Related content

Adjuvant!^© Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer

By Paridaens Robert   Gelber Shari   Cole Bernard   Gelber Richard   Thürlimann Beat   Price Karen   Holmberg Stig   Crivellari Diana   Coates Alan   Goldhirsch Aron  

Breast Cancer Research and Treatment, Vol. 123, Iss. 1, 2010-08 ,pp. : 303-310

Springer Publishing Company

Access to resources Recommend Favorite

Tamoxifen in High-risk Premenopausal Women with Primary Breast Cancer Receiving Adjuvant Chemotherapy. Report from the Danish Breast Cancer Co-operative Group DBCG 82B Trial

By Andersson M.   Kamby C.   Jensen M.-B.   Mouridsen H.   Ejlertsen B.   Dombernowsky P.   Rose C.   Cold S.   Overgaard M.   Andersen J.   Kjaer M.  

European Journal of Cancer, Vol. 35, Iss. 12, 1999-11 ,pp. : 1659-1666

Elsevier

Access to resources Recommend Favorite

Tamoxifen Added to Adjuvant Chemotherapy in Premenopausal Women with Early Breast Cancer: is it Standard Practice or Still a Subject for Study?

By Bramwell V.H.C.   Pritchard K.I.  

European Journal of Cancer, Vol. 35, Iss. 12, 1999-11 ,pp. : 1625-1627

Elsevier

Access to resources Recommend Favorite

Adjuvant endocrine therapy in premenopausal women with breast cancer

By González Martín Antonio   Cruz Susana   Márquez Raúl  

Breast Cancer Research and Treatment, Vol. 123, Iss. 1, 2010-09 ,pp. : 43-47

Springer Publishing Company

Access to resources Recommend Favorite

A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: A report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1

By Sawka C.A.  

Breast Cancer Research and Treatment, Vol. 44, Iss. 3, 1997-07 ,pp. : 211-215

Springer Publishing Company

Access to resources Recommend Favorite